Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21443363 | 0.89 | HSD17B10 (0.61) | HSD17B10RXFP1ALDH1A1CYP2C9HPGD | |
| SCHEMBL10113960 | 0.88 | HSD17B10 (0.72) | HSD17B10RXFP1ALDH1A1CYP2C9HPGD | |
| SCHEMBL17200781 | 0.83 | RXFP1 (0.68) | HSD17B10RXFP1ALDH1A1CYP2C9HPGD | |
| SCHEMBL18166765 | 0.82 | HSD17B10 (0.78) | HSD17B10RXFP1ALDH1A1CYP2C9HPGD | |
| SCHEMBL18166637 | 0.81 | HSD17B10 (0.67) | HSD17B10RXFP1ALDH1A1CYP2C9HPGD | |
| SCHEMBL18166715 | 0.81 | HSD17B10 (0.67) | HSD17B10RXFP1ALDH1A1CYP2C9HPGD | |
| SCHEMBL15075803 | 0.80 | RXFP1 (0.64) | HSD17B10RXFP1ALDH1A1THRBCYP1A2 | |
| SCHEMBL10113920 | 0.79 | PORCN (0.70) | HSD17B10RXFP1ALDH1A1THRBCYP1A2 | |
| SCHEMBL18166643 | 0.77 | RXFP1 (0.72) | HSD17B10RXFP1THRBCYP1A2KMT2A | |
| SCHEMBL27814929 | 0.77 | RXFP1 (0.60) | HSD17B10RXFP1ALDH1A1THRBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414740-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9303002-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| WO-2014081925-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011574-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | HSD17B10 510/4885RXFP1 4525/4885ALDH1A1 553/4885 |
| US-10414740-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | HSD17B10 510/4885RXFP1 4525/4885ALDH1A1 553/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | HSD17B10 631/4885RXFP1 4429/4885ALDH1A1 706/4885 |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | HSD17B10 534/4885RXFP1 4411/4885ALDH1A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.